ИНГИБИТОРЫ ДПП-4: СЕГОДНЯ И ЗАВТРА. ЧЕГО МЫ ЖДЕМ ОТ ИНКРЕТИНСТИМУЛИРУЮЩЕЙ ТЕРАПИИ?
- Авторы: Анциферов МБ1, Аметов АС2, Зилов АВ3, Antsiferov MB4, Ametov AS4, Zilov AV4
-
Учреждения:
- Эндокринологический диспансер Департамента здравоохранения Москвы
- ГБОУ ДПО РМАПО Минздравсоцразвития РФ, Москва
- ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития РФ, Москва
- Выпуск: № 7 (2012)
- Страницы: 81-86
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/279505
- ID: 279505
Цитировать
Полный текст
Аннотация
Ключевые слова
Об авторах
М Б Анциферов
Эндокринологический диспансер Департамента здравоохранения МосквыЭндокринологический диспансер Департамента здравоохранения Москвы
А С Аметов
ГБОУ ДПО РМАПО Минздравсоцразвития РФ, МоскваГБОУ ДПО РМАПО Минздравсоцразвития РФ, Москва
А В Зилов
ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития РФ, МоскваГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития РФ, Москва
M B Antsiferov
A S Ametov
A V Zilov
Список литературы
- Dejager S. Vildagliptine in drug-naive patients with type 2 diabetes: 24 weeks, double blinde, randomized, placebo-controlled, multiple dose study. Horm Met Resp 2007:39:218-23.
- Schweizer A, et al. Diabet Med 2007;24:955-61. Göke B, et al. Horm Metab Res 2008;40:892-95.
- Stokes J, Kannel WB, Wolf, PA, Cupples LA, D Agostino RB. The relative importance of selected risk factors for various manifestations cardiovascular disease among men and women from 35 to 64 years old 30 years of follow-up in the Framingham Study. Circulation 1987;75:65-73.
- Wolf PA, D Agostino RB, Delanger AJ, Kannel WB. Probability of stroke a risk profile from the Framingham study. Stroke 1991;22:312-18.
- Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes.Stroke1996;27:63-8.
- D'Alessio DA, et al. Contains patients on vildagliptin alone and those on vildagliptin plus metformin. J Clin Endocrinol Metab 2009;94:81-8.
- Bosi E, Dotta F, J Y, Goodman M, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009:1-10.
- Bosi, et al. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin. Diabetes care 2007;30(4):890-95.
- Matthews, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab2010;12:780-89.
- Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11(8):804-12.
- Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes II. Mortality results. Diabetes 1970;19:789-815.
- Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10(11):1114-24.
- Fonseca V, et al. Diabetologia 2007;50:1148-55.
- Boschmann, et al. Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients. J Clin Endocrinol Metab 2009;94:846-52.
- Azuma, et al. Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes. J Clin Endocrinol Metab 2008;93:459-64.
- Ahren, et al. Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes. Diabetes care 2004;27(12):2874-80.
- Richter G, Feddersen O, Wagner U, et al. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993;265:374-81.
- Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-19.
- Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev 2007;87:1409-39.
- Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:199-206.
- Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001;50:785-96.
- Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 2007;9:153-65.
- Fred F Ferri. Practical guide to the care of the medical patient. 6 ed. 2004. Br J Diabetes Vasc Dis 2006;6(5):207-15
- DeFronzo RA. Br J Diabetes Vasc Dis 2003;3(1):24-40.
- The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care 2002;25(12):2165-71.